ANI Pharmaceuticals, Inc. (ANIP) revenue and earnings history
ANI Pharmaceuticals, Inc. reported revenue of $883M for fiscal 2025 (year ended Dec 31, 2025), +43.8% on the year before, and net income of $78.3M.
Over 16 years, from fiscal 2009 to fiscal 2025, revenue grew at a compound rate of +50.6% a year.
Revenue and net income, 17 fiscal years
Annual figures, newest first
| Fiscal year | Revenue | Operating income | Net income | Operating cash flow | Capital expenditure | Free cash flow | Stock-based pay | Share buybacks | Dividends paid | Cash at year end | Total debt at year end | Report |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025ended Dec 31, 2025 | $883M+43.8% | $111M | $78.3M | $185M | $13.8M | $171M | $37.9M | $12.2M | $1.16M | $286M | $309M | 10-K |
| 2024 |
The latest quarter, insider trades and fund moves: ANI Pharmaceuticals, Inc. (ANIP) on OQRO.
Common questions
What was ANI Pharmaceuticals, Inc.'s revenue in fiscal 2025?
$883M for the year ended Dec 31, 2025, as reported in its 10-K filed Feb 27, 2026. That is +43.8% on fiscal 2024 ($614M).
How fast has ANI Pharmaceuticals, Inc.'s revenue grown?
From $1.26M in fiscal 2009 to $883M in fiscal 2025: a compound annual growth rate of +50.6% over 16 years. This is arithmetic on the filed figures and says nothing about the years ahead.
Where these figures come from
The SEC’s companyfacts data: every figure ANI Pharmaceuticals, Inc. tagged in XBRL in its annual and quarterly reports since 2009 (some reports carry a few earlier years as comparatives). For each fiscal year OQRO keeps the twelve-month totals from the annual report and the cash and debt at year end, and when a later report restates a year, the later figure. Read again whenever the company files.
Figures are as reported, in US dollars, with no adjustment for acquisitions, disposals or one-off items. Earnings per share are left out because a stock split changes them between reports. This page describes the past and is not investment advice. No language model wrote it.